Intuitive Surgical (ISRG)
(Delayed Data from NSDQ)
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $487.17 +0.55 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $487.17 +0.55 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Zacks News
Genomic Health (GHDX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
We are encouraged by the year-over-year rise in Genomic Health's (GHDX) revenues in Q2, driven by solid performances in the United States and internationally.
ResMed (RMD) Q4 Earnings & Sales Beat on Overall Growth
by Zacks Equity Research
ResMed (RMD) sees solid contributions from domestic and international businesses in Q4.
Pacific Biosciences (PACB) Loss In Line With Estimates in Q2
by Zacks Equity Research
Strong performance in Product revenues boosts Pacific Biosciences (PACB) in Q2. Sequel order improves year over year.
DexCom (DXCM) Beats Q2 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q2 results.
Integer Holdings (ITGR) Beats on Q2 Earnings, '18 View Solid
by Zacks Equity Research
Integer Holdings (ITGR) gains on solid Cardio & Vascular revenues and high organic sales; a solid guidance raises optimism.
CONMED (CNMD) Beats on Q2 Earnings, Raises 2018 Guidance
by Zacks Equity Research
CONMED (CNMD) sees solid domestic and international sales in Q2; raised guidance encourages.
Masimo (MASI) Beats on Q2 Earnings, Raises 2018 Guidance
by Zacks Equity Research
Masimo (MASI) gains from solid segmental performance in Q2; non-invasive technology continues to be in demand.
DaVita (DVA) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
Year-over-year growth in net dialysis and related lab patient service revenues boost DaVita's (DVA) bottom line in Q2.
Becton, Dickinson (BDX) Earnings and Revenues Beat in Q3
by Zacks Equity Research
Becton, Dickinson (BDX) gains from solid segmental and geographical sales in Q3.
PRA Health's (PRAH) Q2 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
PRA Health (PRAH) sees year-over-year double-digit growth in earnings, revenues and net new business in Q2. However, increasing labor-related costs in the Clinical Research wing is a concern.
Express Scripts (ESRX) Q2 Earnings Beat, Network Claims Fall
by Zacks Equity Research
Express Scripts (ESRX) witnesses year-over-year decline in adjusted network claims in Q2, thanks to the loss of certain public sector clients.
AmerisourceBergen (ABC) Beats on Q3 Earnings & Revenues
by Zacks Equity Research
AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and the World Courier business in Q3.
PerkinElmer (PKI) Q2 Earnings & Revenues Top, EPS View Up
by Zacks Equity Research
Solid performance by PerkinElmer's (PKI) DAS and Diagnostics arms is a key positive in Q2. The company saw strength across all major geographies in Asia, Americas, Europe and the BRIC nations.
IDEXX Laboratories (IDXX) Beats on Q2 Earnings, EPS View Up
by Zacks Equity Research
IDEXX Laboratories' (IDXX) stellar performance in Q2 was driven by strong sales at the CAG business.
NuVasive (NUVA) Q2 Earnings Meet Estimates, EPS View Down
by Zacks Equity Research
NuVasive (NUVA) expects robust demand for recently-launched products and positive surgeon conversion efforts as its new Lateral Single-Position Surgery procedure gains traction in the market.
Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Dips
by Zacks Equity Research
At the Home Health and Hospice divisions, Amedisys (AMED) gains traction from solid growth in Medicare and non-Medicare revenues.
Hologic (HOLX) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Solid growth at Hologic's (HOLX) Breast Health and international business drives top line in Q3.
QIAGEN (QGEN) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
QIAGEN's (QGEN) year-over-year revenue growth in Q2 is encouraging. Expansion in operating margin buoys optimism.
Fresenius Medical (FMS) Misses Q2 Earnings & Sales Estimates
by Zacks Equity Research
Lower peritoneal dialysis sales in Q2 hurt Fresenius Medical (FMS); solid geographical performance encourages.
Medical Product Earnings Lineup for Aug 2: ABC, BDX & More
by Zacks Equity Research
Strong R&D focus is likely to be the key driver of the Medical Product space in Q2.
Ecolab (ECL) Q2 Earnings In Line, Revenues Beat Estimates
by Zacks Equity Research
Solid performance in the Global Industrial and Global Institutional segments boost Ecolab's (ECL) top line in Q2.
Illumina (ILMN) Beats on Q2 Earnings, Lifts '18 Guidance
by Zacks Equity Research
Illumina (ILMN) gains on strong consumables growth across its sequencing portfolio with strength in all throughput categories in Q2.
Cardiovascular Systems (CSII) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Cardiovascular Systems (CSII) sees strength in Coronary device and peripheral device segments in Q4.
athenahealth (ATHN) Beats on Q2 Earnings, Raises '19 View
by Zacks Equity Research
An upbeat 2018 guidance instills investor's optimism for athenahealth (ATHN). However, lackluster performance in the Implementation and other segment is a persistent headwind.
The Zacks Analyst Blog Highlights: Apple, Microsoft, Intuitive Surgical and AT&T
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Microsoft, Intuitive Surgical and AT&T